AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca
admin 8 hours agoNew York StateComments Off on AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca1 Views
PressBee – ROCKVILLE, Md. and SHANGHAI, Jan. 18, 2026 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta”), a global clinical-stage biopharmaceutical company focused on
